<DOC>
	<DOCNO>NCT03020797</DOCNO>
	<brief_summary>This pilot trial test perampanel ( Fycompa ; Eisai , Inc. ) ALS patient . The investigator focus safety preliminary sign efficacy . Perampanel approve FDA treatment seizures patient epilepsy . In study , perampanel use off-label adult ALS oral medication dose low end recommend dose range epilepsy . This study consist two treatment arm : perampanel match placebo randomize 1:1 ratio . Subjects receive medication 9 month .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Safety Efficacy Fycompa Subjects With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1. diagnosis ALS 2. first clinical weakness within past 3 year 3. slow vital capacity &gt; = 60 % predict within 1 month treatment 4. may stable dose riluzole least 30 day , otherwise agree initiate riluzole duration trial 5. travel Stony Brook receive medical care 6. must monitor contacted regular interval report subject 's clinical/psychiatric status 1. use tracheostomy mechanical ventilation within last 3 month 2. hepatic insufficiency abnormal liver function 3. renal insufficiency 4. clinically significant psychiatric disorder 5. history malignancy &lt; 5 year prior entry 6. history HIV , clinically significant chronic hepatitis , active infection 7. history stomach intestinal surgery condition could interfere absorption , distribution , metabolism secretion study drug 8. history alcohol substance abuse within 3 month prior entry ( subject instruct refrain alcohol study ) 9. use strong cytochrome P4503A inhibitor inducer , anticonvulsant drug know interact strongly perampanel . 10. pregnancy lactation 11. clinically significant medical condition ( ALS ) would pose risk subject participate 12. know hypersensitivity perampanel 13. currently participate , participate study investigation market compound within 3 month entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>